vs

Side-by-side financial comparison of Leonardo DRS, Inc. (DRS) and Zimmer Biomet (ZBH). Click either name above to swap in a different company.

Zimmer Biomet is the larger business by last-quarter revenue ($2.1B vs $1.1B, roughly 2.0× Leonardo DRS, Inc.). Zimmer Biomet runs the higher net margin — 11.4% vs 9.6%, a 1.8% gap on every dollar of revenue. On growth, Zimmer Biomet posted the faster year-over-year revenue change (9.3% vs 8.1%). Leonardo DRS, Inc. produced more free cash flow last quarter ($376.0M vs $245.9M). Over the past eight quarters, Leonardo DRS, Inc.'s revenue compounded faster (24.1% CAGR vs 3.7%).

Leonardo DRS, Inc. is a United States–based defense contractor. Originally founded as DRS Technologies, Inc. and traded on the NYSE, it was acquired by Leonardo’s predecessor Finmeccanica in 2008. Leonardo DRS provides advanced defense technologies and systems primarily to the U.S. military.

Zimmer Biomet Holdings, Inc. is a publicly traded American medical device company. It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.

DRS vs ZBH — Head-to-Head

Bigger by revenue
ZBH
ZBH
2.0× larger
ZBH
$2.1B
$1.1B
DRS
Growing faster (revenue YoY)
ZBH
ZBH
+1.2% gap
ZBH
9.3%
8.1%
DRS
Higher net margin
ZBH
ZBH
1.8% more per $
ZBH
11.4%
9.6%
DRS
More free cash flow
DRS
DRS
$130.1M more FCF
DRS
$376.0M
$245.9M
ZBH
Faster 2-yr revenue CAGR
DRS
DRS
Annualised
DRS
24.1%
3.7%
ZBH

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
DRS
DRS
ZBH
ZBH
Revenue
$1.1B
$2.1B
Net Profit
$102.0M
$238.3M
Gross Margin
25.4%
64.6%
Operating Margin
11.9%
17.9%
Net Margin
9.6%
11.4%
Revenue YoY
8.1%
9.3%
Net Profit YoY
14.6%
30.5%
EPS (diluted)
$0.38
$1.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DRS
DRS
ZBH
ZBH
Q1 26
$2.1B
Q4 25
$1.1B
$2.2B
Q3 25
$960.0M
$2.0B
Q2 25
$829.0M
$2.1B
Q1 25
$799.0M
$1.9B
Q4 24
$981.0M
$2.0B
Q3 24
$812.0M
$1.8B
Q2 24
$753.0M
$1.9B
Net Profit
DRS
DRS
ZBH
ZBH
Q1 26
$238.3M
Q4 25
$102.0M
$139.4M
Q3 25
$72.0M
$230.9M
Q2 25
$54.0M
$152.8M
Q1 25
$50.0M
$182.0M
Q4 24
$89.0M
$239.5M
Q3 24
$57.0M
$249.1M
Q2 24
$38.0M
$242.8M
Gross Margin
DRS
DRS
ZBH
ZBH
Q1 26
64.6%
Q4 25
25.4%
64.7%
Q3 25
23.1%
72.1%
Q2 25
23.8%
71.5%
Q1 25
22.7%
71.2%
Q4 24
24.0%
71.0%
Q3 24
22.0%
70.5%
Q2 24
22.4%
71.5%
Operating Margin
DRS
DRS
ZBH
ZBH
Q1 26
17.9%
Q4 25
11.9%
6.9%
Q3 25
9.7%
17.6%
Q2 25
8.4%
14.4%
Q1 25
7.4%
15.3%
Q4 24
12.2%
19.2%
Q3 24
9.2%
15.3%
Q2 24
7.3%
18.1%
Net Margin
DRS
DRS
ZBH
ZBH
Q1 26
11.4%
Q4 25
9.6%
6.2%
Q3 25
7.5%
11.5%
Q2 25
6.5%
7.4%
Q1 25
6.3%
9.5%
Q4 24
9.1%
11.8%
Q3 24
7.0%
13.7%
Q2 24
5.0%
12.5%
EPS (diluted)
DRS
DRS
ZBH
ZBH
Q1 26
$1.22
Q4 25
$0.38
$0.71
Q3 25
$0.26
$1.16
Q2 25
$0.20
$0.77
Q1 25
$0.19
$0.91
Q4 24
$0.34
$1.18
Q3 24
$0.21
$1.23
Q2 24
$0.14
$1.18

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DRS
DRS
ZBH
ZBH
Cash + ST InvestmentsLiquidity on hand
$647.0M
$424.2M
Total DebtLower is stronger
$321.0M
$7.5B
Stockholders' EquityBook value
$2.7B
$12.7B
Total Assets
$4.5B
$22.7B
Debt / EquityLower = less leverage
0.12×
0.59×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DRS
DRS
ZBH
ZBH
Q1 26
$424.2M
Q4 25
$647.0M
$591.9M
Q3 25
$309.0M
$1.3B
Q2 25
$278.0M
$556.9M
Q1 25
$380.0M
$1.4B
Q4 24
$598.0M
$525.5M
Q3 24
$198.0M
$569.0M
Q2 24
$149.0M
$420.1M
Total Debt
DRS
DRS
ZBH
ZBH
Q1 26
$7.5B
Q4 25
$321.0M
Q3 25
$326.0M
Q2 25
$331.0M
Q1 25
$335.0M
Q4 24
$340.0M
Q3 24
$345.0M
Q2 24
$351.0M
Stockholders' Equity
DRS
DRS
ZBH
ZBH
Q1 26
$12.7B
Q4 25
$2.7B
$12.7B
Q3 25
$2.6B
$12.8B
Q2 25
$2.6B
$12.5B
Q1 25
$2.6B
$12.4B
Q4 24
$2.6B
$12.5B
Q3 24
$2.5B
$12.4B
Q2 24
$2.4B
$12.7B
Total Assets
DRS
DRS
ZBH
ZBH
Q1 26
$22.7B
Q4 25
$4.5B
$23.1B
Q3 25
$4.2B
$23.5B
Q2 25
$4.1B
$22.9B
Q1 25
$4.1B
$22.2B
Q4 24
$4.2B
$21.4B
Q3 24
$3.9B
$21.7B
Q2 24
$3.8B
$21.5B
Debt / Equity
DRS
DRS
ZBH
ZBH
Q1 26
0.59×
Q4 25
0.12×
Q3 25
0.12×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.14×
Q2 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DRS
DRS
ZBH
ZBH
Operating Cash FlowLast quarter
$425.0M
$359.4M
Free Cash FlowOCF − Capex
$376.0M
$245.9M
FCF MarginFCF / Revenue
35.5%
11.8%
Capex IntensityCapex / Revenue
4.6%
Cash ConversionOCF / Net Profit
4.17×
1.51×
TTM Free Cash FlowTrailing 4 quarters
$227.0M
$1.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DRS
DRS
ZBH
ZBH
Q1 26
$359.4M
Q4 25
$425.0M
$517.4M
Q3 25
$107.0M
$418.7M
Q2 25
$-28.0M
$378.2M
Q1 25
$-138.0M
$382.8M
Q4 24
$443.0M
$506.3M
Q3 24
$59.0M
$395.7M
Q2 24
$34.0M
$369.4M
Free Cash Flow
DRS
DRS
ZBH
ZBH
Q1 26
$245.9M
Q4 25
$376.0M
$442.6M
Q3 25
$77.0M
$363.7M
Q2 25
$-56.0M
$328.1M
Q1 25
$-170.0M
$338.2M
Q4 24
$414.0M
$454.8M
Q3 24
$47.0M
$351.2M
Q2 24
$0
$316.7M
FCF Margin
DRS
DRS
ZBH
ZBH
Q1 26
11.8%
Q4 25
35.5%
19.7%
Q3 25
8.0%
18.2%
Q2 25
-6.8%
15.8%
Q1 25
-21.3%
17.7%
Q4 24
42.2%
22.5%
Q3 24
5.8%
19.3%
Q2 24
0.0%
16.3%
Capex Intensity
DRS
DRS
ZBH
ZBH
Q1 26
Q4 25
4.6%
3.3%
Q3 25
3.1%
2.7%
Q2 25
3.4%
2.4%
Q1 25
4.0%
2.3%
Q4 24
3.0%
2.5%
Q3 24
1.5%
2.4%
Q2 24
4.5%
2.7%
Cash Conversion
DRS
DRS
ZBH
ZBH
Q1 26
1.51×
Q4 25
4.17×
3.71×
Q3 25
1.49×
1.81×
Q2 25
-0.52×
2.48×
Q1 25
-2.76×
2.10×
Q4 24
4.98×
2.11×
Q3 24
1.04×
1.59×
Q2 24
0.89×
1.52×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons